Efficacy of metformin in the treatment of NIDDM: Meta-analysis

Diabetes Care

Volumn 22, Issue 1, 1999, Pages 33-37

  Johansen, Klaus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MEDLARS; MEDLINE; METFORMIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0032929173     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.1.33     Document Type: Article

References (23)

1. Bailey CJ, Turner RC: Drug therapy: metformin. N Engl J Med 334:574-579, 1996
2. Bracken MB: Statistical methods for analysis of effects of treatment in overviews of randomized trials. In Effective Care of the Newborn Infant. Sinclair JC, Bracken MB, Eds., Oxford, U.K., Oxford University Press, 1992, p. 13-18
3. Dickersin K, Berlin JA: Meta-analysis: state-of-the-science. Epidemiol Rev 14:154-176, 1992
4. Lalor BC, Bhatnagar D, Winocour PH, Ishola M, Arrol S, Brading M, Durrington PN: Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet Med 7:242-245, 1990
5. Teupe B, Bergis K: Prospective randomized 2-year clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab 17:213-217, 1991
6. Dornan TL, Heller SR, Peck GM, Tattersall RB: Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 14:342-344, 1991
7. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 16:621-629, 1993
8. Johnson AB, Webster JM, Sum C-F, Heseltine L, Argyraki M, Cooper BG, Taylor R: The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 42:1217-1222, 1993
9. Tessari P, Biolo G, Bruttomesso D, Inchiostro S, Panebiancho G, Vedovato M, Fongher C, Tiengo A: Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes. J Clin Endocrinol Metab 79:1553-1560, 1994
10. DeFronzo RA, Goodman AM, The Multicenter Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
11. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for 3 years. BMJ 310:83-88, 1995
12. Grant PJ: The effects of high- and medium-dose metformin therapy on cardiovscular risk factors in patients with type II diabetes. Diabetes Care 19:64-66, 1996
13. Rains SGH, Wilson GA, Richmond W, Elkeles RS: The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 5:653-658, 1988
14. Collier A, Watson HHK, Patrick AW, Ludlam CA, Clarke BF: Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 15:420-425, 1989
15. Josephkutty S, Potter JM: Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet Med 7:510-514, 1990
16. Hermann LS, Karlsson J-E, Sjostrand Å: Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. Eur J Clin Pharmacol 41:263-265, 1991
17. Noury J, Nandeuil A: Comparative 3-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabete Metab 17:209-212, 1991
18. Boyd K, Rogers C, Boreham C, Andrews WJ, Hadden D: Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes Res 19:69-76, 1992
19. Hermann LS, Kjellstrom T, Schersten B, Lindgarde F, Sitzen P-O, Melander A: Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. Diabetes Care 17:1100-1109, 1994
20. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IRF: 1-year comparative trials of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab 21:394-400, 1994
21. Clarke BF, Duncan LJP: Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet i:123-126, 1968
22. Campbell IW, Howlett HCS: Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 11:557-562, 1995
23. Clarke BF, Campbell IW: Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 2:1576-1578, 1977